الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 191 |  |  |
| | | from | 191 | | |
Abstract
NAFLD is characterized by an excessive buildup of lipids, which can lead to hepatic illnesses such cirrhosis, fibrosis, and steatohepatitis. NAFLD frequently coexists with metabolic syndromes such obesity, diabetes mellitus, hypertension, and hyperlipidemia because it is a multifactorial condition. It has been observed that changes in lifestyle, such dietary adjustments and weight loss, are helpful in treatment of NAFLD.
This work was designed to evaluate the ameliorative effects of nano-silymarin, nano-chitosan and SILCSNPs in NAFLD treatment. We hypothesized that nano-silymarin, nano-chitosan and SILCSNPs have a beneficial effect on lipid profile (triglycerides, cholesterol, HDL and LDL), hepatic antioxidant enzymes (catalase and SOD), hepatic malondialdehyde (MDA), glycemic index (glucose and insulin), liver function enzymes (ALT and AST) and mRNA expression of lipogenesis-related genes including ACC and FASN as well as fatty acids catabolism-related genes including CPT-1, PPAR-α and PGC-1α were measured. In addition, mRNA expression of glucose metabolism-related genes including GLP-1 and IGF-1 were assessed.